The 5 Things You Need to Know about the New Cholesterol Guidelines for the ABIM & USMLE exams

With all the recent revisions to hypertension goals, breast cancer screening, prostate serum antigen (PSA) testing, etc., you’d think medical societies were deliberately trying to confuse medical students and internal medicine residents preparing for the USMLE and ABIM examinations. Fortunately, there isn’t any evidence of any diabolical agenda. At the same time though, because the folks at the ABIM aren’t particularly specific about when to start adopting guidelines (see image below), it’s the responsibility of each exam-taker to be aware of what changes have occurred since we were formally taught a particularly topic in a med school lecture, morning report, or noon conference.

 

IM-Boards-Cholesterol-Guidelines

 

Previously, I wrote about the major take-home points from the new JNC8 hypertension guidelines. Around that time, in November 2013, the American College of Cardiology (ACC) and the American Heart Association (AHA) along with the National Heart, Lung, and Blood Institute replaced the previous Adult Treatment Panel (ATP) guidelines on cholesterol management as well. This new set of cholesterol guidelines made headlines worldwide and created a mound of controversy. The debate has died down and major healthcare organizations like Kaiser Permanente have incorporated them into their own guidelines. Thus, we can now establish some key summary points from the guidelines.

 

 

1. Discontinue those LDL standing orders
One of the most profound changes was the removal of the target LDL levels in patients with cardiovascular disease or its equivalents. These individuals are no longer treated to a goal of 100mg/dL, ideally 70mg/dL. Indeed, no randomized clinical trials has proven benefit of treating to target LDL levels. One benefit of this update is that you won’t have to order as many labs on your patients–no more q3 month lipid panels. For patients, this means a reduction in needle sticks and laboratory co-pays while getting the benefit of reduced adverse cardiovascular events.

 

2. Four groups of patients should be treated with statins
Earlier, statin use was recommended only for those patients with a high 10-year cardiovascular risk of 20%. However, now there are many more patients who will be eligible for statin medication, representing perhaps the thorniest issue with the new guidelines. The four groups of patients who should be prescribed statins are:

– Clinical atherosclerotic cardiovascular disease

– LDL cholesterol greater than or equal to 190mg/dL

– Diabetics aged 40 to 75 years

– LDL-cholesterol levels between 70 and 189mg/dL and a 10-year risk of atherosclerotic cardiovascular disease greater than or equal to 7.5%

2013 ACC Hyperlipidemia Internal Medicine

 

3. If it’s not a statin, don’t prescribe it for hyperlipidemia

Others may affect the lab values, but statins (HMG-CoA reductase inhibitors) are the only lipid-lowering medications that have been shown to reduce cardiovascular events and mortality in both primary and secondary prevention trials. Non-statin therapies don’t offer any benefit. We could see this coming when ezetemide (Zetia) was found to be ineffective in lowering heart attack or stroke risk despite lowering LDL levels by 15 to 30 percent. Enthusiasm for non-statins was further dampened with the 2011 AIM-HIGH trial. This study of 3414 patients with stable coronary artery disease and low HDL levels was prematurely terminated when the adverse event rate (myocardial infarction, ischemic stroke, death from coronary artery disease, acute coronary syndrome hospitalization and revascularization) was 16.4% in the niacin group and 16.2% in the placebo group.

 

4. Out with Framingham, In with Pooled Cohort Risk Assessment
A town in Massachusetts, Framingham is best remembered for the famous study that led to the establishment of cardiac risk factors. The new guidelines replaces this risk calculator with the new Pooled Cohort Risk Assessment, which incorporates ethnicity and gender. The tool calculates risk of fatal and nonfatal stroke in addition to coronary heart disease. The patient’s calculated risk is important because it can determine if the patient receives a low-dose or a high-dose statin.

 

5. Dose matters
Earlier guidelines didn’t emphasize the strength of the statin. Now we differentiate the medications into moderate- and high-intensity groups. 2013 ACC Hyperlipidemia Internal Medicine2

 

High-intensity statins are simply:
  • Rosuvastatin 20-40mg daily
  • Atorvastatin 40-80mg daily

 

They are recommended for the following:

  • Any patient–regardless of LDL level–with atherosclerotic cardiovascular disease (ASCVD)
  • Any patient with an LDL cholesterol greater than 190mg/dL
  • Diabetic patient between 40-75 years with 10-year risk of ASCVD greater than or equal to 7.5%

 

Moderate-intensity statins include the following:
  • Atorvastatin 10-20mg daily
  • Rosuvastatin 5-10mg daily
  • Simvastatin 20-40mg daily
  • Pravastatin 40-80mg daily
  • Lovastatin 40mg daily
  • Fluvastatin XL 80mg daily
  • Fluvastatin 40mg twice daily
  • Pitavastatin 2-4mg daily

 

They are used for the remaining patient groups:

– Diabetic patient between 40-75 years with 10-year risk of ASCVD less than 7.5%

– Patients with 10-year risk of ASCVD greater than 7.5%

 

So there you have it. In 5 easy-to-follow bullet points, you have the knowledge you need to answer any question covering the new Cholesterol Guidelines on the ABIM or USMLE exams.




Got something to add?

Please log In or register for a free account to write a comment.